MIST News and Press, Milestone Pharmaceuticals Inc. From 11/13/23

2023-11-13 06:58:59 ET More on Milestone Pharmaceuticals Seeking Alpha’s Quant Rating on Milestone Pharmaceuticals Historical earnings data for Milestone Pharmaceuticals Financial information for Milestone Pharmaceuticals For further details see: M...

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 Canada NewsWire E tripamil, an investigational drug, showed statistically significant reduction in ventricula...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Milestone Pharmaceuticals Inc. (MIST) is expected to report $-0.38 for Q3 2023

Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR Canada NewsWire Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm , MD, and Sean Pokorney , MD ...

Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil Canada NewsWire Submission seeks approval for treatment of an abnormal heart rhythm, Paroxysmal Supraventricular Tachycardia or PSVT Comprehensive data packa...

Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023 Canada NewsWire MONTREAL and CHARLOTTE, N.C. , Sept. 27, 2023 /CNW/ -- Milestone Pharmaceut...

Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference Canada NewsWire MONTREAL and CHARLOTTE, N.C. , Sept. 5, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on ...

2023-08-10 12:24:31 ET Milestone Pharmaceuticals press release ( NASDAQ: MIST ): Q2 GAAP EPS of -$0.37 beats by $0.02 . As of June 30, 2023, Milestone had cash, cash equivalents, and short-term investments of $87.6 million and 33.4 million common shares issued and outs...

Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update Canada NewsWire NDA submission for etripamil in patients with PSVT expected in October 2023 Data featured during oral session at Heart Rhythm 2023 A...